U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H28O3
Molecular Weight 328.4452
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SEGESTERONE

SMILES

[H][C@@]12CC(=C)[C@](O)(C(C)=O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=SFLXYFZGKSGFKA-XUDSTZEESA-N
InChI=1S/C21H28O3/c1-12-10-19-18-6-4-14-11-15(23)5-7-16(14)17(18)8-9-20(19,3)21(12,24)13(2)22/h11,16-19,24H,1,4-10H2,2-3H3/t16-,17+,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI
Molecular Formula C21H28O3
Molecular Weight 328.4452
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Elcometrine (Segesterone acetate, Nestorone) is a steroidal progestin which is used as a hormonal contraceptive and as a treatment of endometriosis. Upon oral administration, Nestorone undergoes rapid metabolism and inactivation. Several clinical trials have been performed with Nestorone administered via subdermal implants.

Originator

Approval Year

2018
400
Targets

Targets

Primary TargetPharmacologyConditionPotency
Progesterone receptor
60
Target ID: P06401
Gene ID: 5241.0
Gene Symbol: PGR
Target Organism: Homo sapiens (Human)
Agonist
2637
 56.0 nM [EC50]
Agonist
2637
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1133
Unknown

Approved Use

Unknown
Preventing
Phase III
651
ELMETRIN

Approved Use

Unknown
Preventing
Approved
8307
ANNOVERA

Approved Use

is indicated for use by females of reproductive potential to prevent pregnancy

Launch Date

1.53377282E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
294 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1147 pg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
942.9 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29409834/
200 μg 1 times / day steady-state, vaginal
dose: 200 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ESTRADIOL
ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.9 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
15 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
38685.7 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29409834/
200 μg 1 times / day steady-state, vaginal
dose: 200 μg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ESTRADIOL
ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
4.5 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
0.15 mg 1 times / day steady-state, vaginal
dose: 0.15 mg
route of administration: Vaginal
experiment type: STEADY-STATE
co-administered: ETHINYL ESTRADIOL
ETHINYL ESTRADIOL
 SEGESTERONE ACETATE serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Disc. AE: Menometrorrhagia, Migraine headache...
Other AEs: Migraine headache, Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Menometrorrhagia (1.7%)
Migraine headache (1.3%)
Vulvovaginal mycotic infection (1.3%)
Nausea and vomiting (1.2%)
Uterine myoma expulsion (1.4%)
Other AEs:
Migraine headache (38.6%)
Nausea and vomiting (25%)
Vulvovaginal mycotic infection (14.5%)
Abdominal pain lower (13.3%)
Dysmenorrhea (12.5%)
Vaginal discharge (11.8%)
Genitourinary tract infection (10%)
Breast discomfort (9.5%)
Disorder menstrual (7.5%)
Diarrhea (7.2%)
Pruritus genital (5.5%)
Thrombosis NOS (>= 2 patients)
Psychiatric disorder NOS (>= 2 patients)
Drug hypersensitivity (>= 2 patients)
Abortions spontaneous (>= 2 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
AEs

AEs

AESignificanceDosePopulation
Nausea and vomiting 1.2%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Migraine headache 1.3%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Vulvovaginal mycotic infection 1.3%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Uterine myoma expulsion 1.4%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Menometrorrhagia 1.7%
Disc. AE
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Genitourinary tract infection 10%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Vaginal discharge 11.8%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Dysmenorrhea 12.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Abdominal pain lower 13.3%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Vulvovaginal mycotic infection 14.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Nausea and vomiting 25%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Migraine headache 38.6%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Pruritus genital 5.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Diarrhea 7.2%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Disorder menstrual 7.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Breast discomfort 9.5%
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Abortions spontaneous >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Drug hypersensitivity >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Psychiatric disorder NOS >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Thrombosis NOS >= 2 patients
0.15 mg 1 times / day multiple, vaginal
Recommended
Dose: 0.15 mg, 1 times / day
Route: vaginal
Route: multiple
Dose: 0.15 mg, 1 times / day
Co-administed with::
ethinyl estradiol(0.013 mg/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
healthy, 18 - 40 years
n = 2308
Health Status: healthy
Age Group: 18 - 40 years
Sex: F
Population Size: 2308
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf
Page: 13
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1670

inhibitor
1532

inducer
753
inhibitor
1695

inducer
372
inhibitor
1789

inducer
97
inhibitor
1570

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1463

CYP2A6
670

CYP2B6
770

CYP2C8
869

CYP2C19
1410

CYP2E1
846
CYP1A2
671

CYP2B6
521

CYP2C19
283

CYP3A5
76
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1620
 unlikely
CYP1A2
1620
 unlikely
CYP2A6
702
 unlikely
CYP2B6
946
 unlikely
CYP2B6
946
 unlikely
CYP2C19
1484
 unlikely
CYP2C19
1484
 unlikely
CYP2C8
923
 unlikely
CYP2C9
1747
 unlikely
CYP2C9
1747
 unlikely
CYP2D6
1826
 unlikely
CYP2D6
1826
 unlikely
CYP2E1
929
 unlikely
CYP3A4
1857
 unlikely
CYP3A4
1857
 unlikely
CYP3A5
130
 unlikely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1670
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1603
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEMBL
CHEMBL2107778
ChemIDplus
7690086
https://chem.nlm.nih.gov/chemidplus/id/0007690086
Compound Cloud
11823650
DrugBank
DB14584
https://www.drugbank.ca/drugs/DB14584
EPA DSSTox
DTXSID00998190
https://comptox.epa.gov/dashboard/DTXSID00998190
KEGG
D10987
http://www.genome.jp/dbget-bin/www_bget?dr:D10987
SureChEMBL
SCHEMBL7053392
https://www.surechembl.org/chemical/SCHEMBL7053392
Wikidata
Q24882947
ZINC
ZINC000033964021
http://zinc15.docking.org/substances/ZINC000033964021
PubMed

PubMed

TitleDatePubMed
Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
2007 Jun
Relative progestational and androgenic activity of four progestins used for male hormonal contraception assessed in vitro in relation to their ability to suppress LH secretion in the castrate male rat.
2010 Oct 26
Patents

Patents

US 3262950
2

Sample Use Guides

In Vivo Use Guide
One ANNOVERA™ (segesterone acetate and ethinyl estradiol) should be placed in the vagina. For maximum contraceptive effectiveness, ANNOVERA™ is to remain in the vagina continuously for 21 days (3 complete weeks). It is removed for a 1-week dose-free interval, and during this time a withdrawal bleed usually occurs.
Route of Administration: Vaginal
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:44:01 UTC 2022
Edited
by admin
on Fri Dec 16 17:44:01 UTC 2022
Record UNII
09Q5UV3747
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SEGESTERONE
INN   USAN  
USAN   INN  
Official Name English
17-Hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione
Systematic Name English
segesterone [INN]
Common Name English
Segesterone [WHO-DD]
Common Name English
SEGESTERONE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C776
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
Code System Code Type Description
INN
8221
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
EPA CompTox
DTXSID00998190
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
DRUG BANK
DB14584
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
LACTMED
Segesterone
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
USAN
DE-08
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
ChEMBL
CHEMBL2107778
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
NCI_THESAURUS
C66532
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
WIKIPEDIA
Segesterone
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
CAS
7690-08-6
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
FDA UNII
09Q5UV3747
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
PUBCHEM
11823650
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
DAILYMED
09Q5UV3747
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
RXCUI
2055978
Created by admin on Fri Dec 16 17:44:01 UTC 2022 , Edited by admin on Fri Dec 16 17:44:01 UTC 2022
PRIMARY
Related Record Type Details
Structure of SEGESTERONE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966